Floatz logo

Therapeutic Asset Ratings

9,920 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nintedanib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Northwestern UniversityP1CC (43)
Nintedanib
Interstitial Lung Disease
Shenzhen Resproly Biopharmaceutical Co., LtdP1CC (43)
Niraparib
Familial Ovarian Carcinoma
University of WashingtonP1CC (43)
Niraparib
Hereditary Breast Carcinoma
University of WashingtonP1CC (43)
Niraparib
Rectal Cancer
University of IowaP1CC (43)
Niraparib
Rectal Neoplasm
University of IowaP1CC (43)
Nivestim
Plasmablastic Lymphoma
City of Hope Medical CenterP1CC (43)
Nivestim
Metastatic Carcinoma In The Bone
Albert Einstein College of MedicineP1CC (43)
Nivolumab
Medullary Thyroid Gland Carcinoma
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Autoimmune Disease
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Breast Adenocarcinoma
Mayo ClinicP1CC (43)
Nivolumab
Primary Melanoma Of The Central Nervous System
M.D. Anderson Cancer CenterP1CC (43)
Nivolumab
Crohn Disease
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Dermatomyositis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Diffuse Glioma, H3 G34 Mutant
Andrew P. GrovesP1CC (43)
Nivolumab
Anaplastic Astrocytoma
University of FloridaP1CC (43)
Nivolumab
Grade III Glioma
Sabine Mueller, MD, PhDP1CC (43)
Nivolumab
Histiocytic And Dendritic Cell Neoplasm
Mayo ClinicP1CC (43)
Nivolumab
Inflammatory Bowel Disease
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Invasive Breast Carcinoma
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Malignant Leptomeningeal Tumor
M.D. Anderson Cancer CenterP1CC (43)
Nivolumab
Meningeal Melanocytoma
M.D. Anderson Cancer CenterP1CC (43)
Nivolumab
Malignant Conjunctival Melanoma
Fred Hutchinson Cancer CenterP1CC (43)
Nivolumab
Multiple Sclerosis
National Cancer Institute (NCI)P1CC (43)
Nivolumab
Oligoastrocytoma
University of FloridaP1CC (43)
Showing 3476 to 3500 of 9,920 assets
PreviousPage 140 of 397Next